Ferroptosis in Neurological Diseases: Moving Towards Therapeutic Intervention

Why It Matters

Targeting ferroptosis could halt or reverse neuronal loss, addressing unmet needs in diseases with limited disease‑modifying treatments. Successful translation promises new drug pipelines and biomarkers for precision neurology.

Key Takeaways

• Ferroptosis drives neuronal loss in stroke and Alzheimer.
• GPX4 and FSP1 are key ferroptosis suppressors.
• Selenium, NAC, and ebselen show neuroprotective promise.
• Lipid peroxidation biomarkers correlate with disease severity.
• Clinical trials targeting iron metabolism are emerging.

Pulse Analysis

The brain’s high metabolic rate and abundant polyunsaturated lipids make it uniquely vulnerable to ferroptosis, an iron‑driven, non‑apoptotic cell death pathway first described in 2012. Recent lipidomics and iron‑homeostasis studies have linked uncontrolled lipid peroxidation to the progressive loss of neurons in Alzheimer’s, Parkinson’s, and ischemic injury, positioning ferroptosis as a unifying mechanism across disparate neurodegenerative conditions. By mapping the molecular circuitry—GPX4’s lipid‑hydroperoxide detoxification, FSP1’s CoQ10‑mediated antioxidant shield, and DHODH’s mitochondrial defense—researchers have identified actionable nodes that can be modulated pharmacologically.

Therapeutic exploration is rapidly expanding beyond basic science. Selenium‑based GPX4 activators, the glutathione precursor N‑acetylcysteine, and the synthetic antioxidant ebselen have shown efficacy in rodent models of stroke and multiple sclerosis, reducing iron‑induced oxidative damage and preserving cognitive function. Parallel efforts focus on repurposing existing iron chelators and vitamin E analogues, while novel small‑molecule inhibitors of lipid‑peroxidizing enzymes such as ACSL4 are entering pre‑clinical pipelines. Early clinical trials now assess safety and biomarker response, leveraging brain‑specific lipid peroxidation signatures to stratify patients likely to benefit from ferroptosis‑targeted interventions.

Despite promising data, several hurdles remain before ferroptosis inhibitors become standard neuro‑therapeutics. The blood‑brain barrier limits drug delivery, and long‑term suppression of lipid peroxidation may interfere with physiological signaling pathways. Moreover, reliable, non‑invasive biomarkers are needed to monitor treatment response and disease progression. Ongoing collaborations between academic laboratories, biotech firms, and regulatory agencies aim to resolve these challenges, with the ultimate goal of delivering disease‑modifying therapies that can halt or reverse neurodegeneration by curbing ferroptotic cell death.